US faces ethical issues after gene therapy deathBMJ 2000; 320 doi: http://dx.doi.org/10.1136/bmj.320.7235.602/d (Published 04 March 2000) Cite this as: BMJ 2000;320:602
- Janice Hopkins Tanne
- New York
Gene therapy is no different from other kinds of risky medical research, said Dr Arthur Caplan, professor and director of the Center for Bioethics at the University of Pennsylvania in Philadelphia, speaking at the New York Academy of Sciences earlier this week. Better regulation of all research is needed.
A gene therapy experiment at the University of Pennsylvania led to the death of Jesse Gelsinger, an 18 year old man with an inherited metabolic disorder. Dr Caplan, a well known ethicist and author, was not involved in the experiment.
Ethical issues about genetics have been …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial